文献速递口腔修复与种植

糖尿病/高血糖对种植修复患者种植周生物标志物及临床和影像学结局的影响:系统评价与Meta分析

Effects of diabetes/hyperglycemia on peri-implant biomarkers and clinical and radiographic outcomes in patients with dental implant restorations: A systematic review and meta-analysis.
PubMed 文献 · Clin Oral Implants Res · 2022-10-26

该系统评价与Meta分析检索至2022年3月,纳入10项研究共634例参与者,最长随访6年。结果显示糖尿病/高血糖组种植周龈沟液晚期糖基化终产物及IL-6、TNF-α、IL-8、RANKL显著高于健康组,种植体稳定商值、探诊出血率、探诊深度和边缘骨丧失显著更差,且HbA1c水平与AGE累积、PD和MBL呈剂量反应关系。

要点

  • 糖尿病/高血糖组种植周龈沟液AGEs水平显著高于健康组(p<.01)。
  • HbA1c<10%患者种植体存活率100%,未受影响。
  • HbA1c升高与PICF中AGE累积、PD和MBL恶化呈剂量反应关系。

核心结论

  • 糖尿病/高血糖可上调骨代谢负性调节因子并损害种植周健康。
  • HbA1c水平与PICF中AGE累积、PD和MBL之间存在剂量反应关系。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase和Cochrane Central Register of Controlled Trials数据库至2022年3月。
  • 纳入报告不同血糖状态(HbA1c)患者种植周生物标志物及临床和影像学结局的研究,共10项研究、634例参与者,功能状态下最长随访6年。
  • 进行了Meta分析、敏感性分析、剂量反应Meta分析(DRMA)和稳健误差Meta回归(REMR)。

主要发现

  • DM/HG组种植周龈沟液(PICF)中晚期糖基化终产物(AGEs)水平显著高于健康组(p<.01)。
  • 亚组分析显示DM/HG组骨代谢负性调节因子(包括IL-6、TNF-α、IL-8和RANKL)显著高于健康组(p=.01)。
  • HbA1c水平低于10%的患者种植体存活率(100%)未受影响。
  • DM/HG组种植体稳定商值(ISQ)、探诊出血率(BOP%)、探诊深度(PD)和边缘骨丧失(MBL)结局显著差于健康组(分别为p=.04、<0.01、0.01、<0.01)。
  • DRMA结果显示PICF中AGE累积、PD和MBL随HbA1c水平升高(<6%、6-8%、>8%)呈剂量反应依赖性恶化(分别为p=.04、0.02、<0.01)。

关键数值与推荐

  • DM/HG组PICF中AGEs水平显著高于健康组(p<.01)。
  • DM/HG组IL-6、TNF-α、IL-8和RANKL显著高于健康组(p=.01)。
  • HbA1c<10%患者种植体存活率为100%。
  • DM/HG组ISQ、BOP%、PD和MBL显著差于健康组(p=.04、<0.01、0.01、<0.01)。
  • HbA1c分层(<6%、6-8%、>8%)与PICF中AGE累积、PD和MBL呈剂量反应关系(p=.04、0.02、<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study is to systematically analyze the effects of diabetes mellitus/hyperglycemia (DM/HG) on peri-implant biomarkers and clinical and radiographic outcomes in patients undergoing implant treatment. MATERIALS AND METHODS: PubMed, Embase, and the Cochrane Central Register of Controlled Trials databases were searched up to March 2022. Studies reporting on peri-implant biomarkers, and clinical and radiographic outcomes in patients with different glycemic status levels (HbA1c) were included. Several analyses were conducted, such as meta-analysis, sensitivity analysis, dose-response meta-analysis (DRMA), and robust error meta-regression (REMR). RESULTS: A total of 10 studies and 634 participants were included for analysis, with a maximum follow-up of six years in function. The level of advanced glycation end products (AGEs) in peri-implant crevicular fluid (PICF) was significantly higher in the DM/HG group than in the healthy group (p < .01). Subgroup analyses showed that a set of negative regulators of bone metabolism (including IL-6, TNF-α, IL-8, and RANKL) were significantly higher in the DM/HG group (p = .01). Implant survival rate (100%) was not compromised in patients with an HbA1c level less than 10%. Outcomes of implant stability quotient (ISQ) values, bleeding on probing rate (BOP%), probing depth (PD), and marginal bone loss (MBL) in the DM/HG group were significantly worse than those in the healthy group (p = .04, <0.01, 0.01, <0.01, respectively). DRMA results showed AGE accumulation in PICF, PD, and MBL worsened in a dose-response dependent manner with elevated HbA1c levels (<6%, 6-8%, >8%; p = .04, 0.02, <0.01, respectively). CONCLUSIONS: DM/HG can upregulate negative regulators of bone metabolism and compromise peri-implant health. In addition, there are dose-response relationships between HbA1c levels and AGE accumulation in PICF, PD, and MBL.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. Lv X, Zou L, Zhang X, et al. Effects of diabetes/hyperglycemia on peri-implant biomarkers and clinical and radiographic outcomes in patients with dental implant restorations: A systematic review and meta-analysis. Clin Oral Implants Res. 2022. PMID: 36251562. doi:10.1111/clr.14010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。